This is a preview of subscription content, log in via an institution to check access.
Reference
Hagan LM, et al. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 HCV in interferon ineligible/intolerant individuals. Hepatology : 28 Mar 2014. Available from: URL: http://doi.org/10.1002/hep.27151
Rights and permissions
About this article
Cite this article
Sofosbuvir + simeprevir dominates sofosbuvir + ribavirin. PharmacoEcon Outcomes News 700, 10 (2014). https://doi.org/10.1007/s40274-014-1179-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1179-2